Trial Profile
A Phase II Study of OSI 774 (IND Number 63383) in Combination With Celecoxib (Celebrex, Pharmacia) as Second-Line Therapy in Advanced Non-Small Cell Lung Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Celecoxib (Primary) ; Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Biomarker; Therapeutic Use
- 21 Feb 2008 Status changed from in progress to completed.
- 04 Sep 2005 New trial record.